 Tumor Burden
"Tumor Burden" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
| Descriptor ID |
D047368
|
| MeSH Number(s) |
E05.041.124.892
|
| Concept/Terms |
Tumor Burden- Tumor Burden
- Burden, Tumor
- Tumor Load
- Load, Tumor
- Loads, Tumor
- Tumor Loads
Tumor Weight- Tumor Weight
- Tumor Weights
- Weight, Tumor
- Weights, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Burden".
Below are MeSH descriptors whose meaning is more specific than "Tumor Burden".
This graph shows the total number of publications written about "Tumor Burden" by people in this website by year, and whether "Tumor Burden" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 3 | 4 | | 2007 | 0 | 2 | 2 | | 2008 | 2 | 7 | 9 | | 2009 | 0 | 5 | 5 | | 2010 | 2 | 11 | 13 | | 2011 | 1 | 8 | 9 | | 2012 | 0 | 16 | 16 | | 2013 | 1 | 9 | 10 | | 2014 | 1 | 12 | 13 | | 2015 | 2 | 12 | 14 | | 2016 | 1 | 13 | 14 | | 2017 | 0 | 16 | 16 | | 2018 | 1 | 11 | 12 | | 2019 | 2 | 4 | 6 | | 2020 | 1 | 7 | 8 | | 2021 | 0 | 7 | 7 | | 2022 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Burden" by people in Profiles.
-
Marinelli JP, Killeen DE, Schnurman Z, Nassiri AM, Hunter JB, Lees KA, Lohse CM, Roland TJ, Golfinos JG, Kondziolka D, Link MJ, Carlson ML. Spontaneous Volumetric Tumor Regression During Wait-and-Scan Management of 952 Sporadic Vestibular Schwannomas. Otol Neurotol. 2022 10 01; 43(9):e1034-e1038.
-
Marinelli JP, Schnurman Z, Killeen DE, Nassiri AM, Hunter JB, Lees KA, Lohse CM, Roland JT, Golfinos JG, Kondziolka D, Link MJ, Carlson ML. Long-term natural history and patterns of sporadic vestibular schwannoma growth: A multi-institutional volumetric analysis of 952 patients. Neuro Oncol. 2022 08 01; 24(8):1298-1306.
-
Wellberg EA, Corleto KA, Checkley LA, Jindal S, Johnson G, Higgins JA, Obeid S, Anderson SM, Thor AD, Schedin PJ, MacLean PS, Giles ED. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer. Breast Cancer Res. 2022 06 20; 24(1):42.
-
Patten LW, Blatchford P, Strand M, Kaizer AM. Assessing the performance of different outcomes for tumor growth studies with animal models. Animal Model Exp Med. 2022 09; 5(3):248-257.
-
Manzoor NF, Nassiri AM, Sherry AD, Dang S, Yancey KL, Monsour M, Perkins EL, Khattab MH, Thompson RC, O'Malley MR, Bennett ML, Rivas AC, Haynes DS. Predictors of Recurrence After Sub-total or Near-total Resection of Vestibular Schwannoma: Importance of Tumor Volume and Ventral Extension. Otol Neurotol. 2022 06 01; 43(5):594-602.
-
Peng J, Kim DD, Patel JB, Zeng X, Huang J, Chang K, Xun X, Zhang C, Sollee J, Wu J, Dalal DJ, Feng X, Zhou H, Zhu C, Zou B, Jin K, Wen PY, Boxerman JL, Warren KE, Poussaint TY, States LJ, Kalpathy-Cramer J, Yang L, Huang RY, Bai HX. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2022 02 01; 24(2):289-299.
-
Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Nat Commun. 2022 01 10; 13(1):97.
-
Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, Ahrendt S, Gleisner A, Schulick RD, Del Chiaro M. Prognosis Based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann Surg. 2022 01 01; 275(1):175-181.
-
Barrag?n-Carrillo R, Mateos-Corella S, Ortiz-Hidalgo C, Izquierdo-Echavarri E, Castillejos-Molina R, Angel M, Barragan-Arteaga I, Flaig T, Bourlon MT. Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor. Oncology (Williston Park). 2021 12 17; 35(12):816-819.
-
Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 2021 12 07; 37(10):110085.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|